If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GLP-1 / glucagon dual receptor agonist (IBI362 / LY3305677)
Supply and ordering
Ask sales about Mazdutide availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
Mazdutide (development codes IBI362 / LY3305677) is an investigational dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics in partnership with Eli Lilly. Unlike the GIP/GLP-1 dual agonist class (Tirzepatide) or the GIP/GLP-1/glucagon tri-agonist class (Retatrutide), Mazdutide engages only the GLP-1 and glucagon arms, without GIP, which positions it as a mechanistically distinct alternative for buyers studying glucagon-pathway pharmacology in isolation from GIP signaling. The molecule is in Phase 3 development in China for chronic weight management and type 2 diabetes, with regulatory approval signals expected on a faster timeline in the Chinese market than Western markets. PeptideXpo supplies Mazdutide acetate as a lyophilized powder to a ≥99.0% HPLC purity specification with batch-specific COA. Every released lot comes with its batch COA covering peak-integration HPLC purity and ESI mass-spec identity; water content and counter-ion are available on request and listed on the COA when tested, and sequence verification by LC-MS/MS is available when required by a written analytical scope. The 10 mg standard fill size covers typical research aliquot work; larger fills for sustained-research programs are available through the OEM service.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: academic and contract research laboratories.
Specifications
Also available as a nasal spray (US stock)
Besides lyophilized vials, Mazdutide is stocked in the US as a ready-to-use nasal spray.
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COAMazdutide 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Investigational compound in Phase 3 development (Innovent / Eli Lilly); not approved as a finished drug at the time of writing. Supplied for research use only. CAS commonly cited but should be verified per batch COA.
Selected literature
Frequently asked questions
All three are multi-receptor incretin-pathway peptides, but the receptor coverage differs: Tirzepatide is GIP + GLP-1, Mazdutide is GLP-1 + glucagon, Retatrutide is GIP + GLP-1 + glucagon. The presence or absence of the glucagon arm is the key mechanistic divider, adding glucagon receptor agonism contributes hepatic-energy-expenditure effects on top of the incretin-driven glycemic and weight effects. Mazdutide isolates the GLP-1 + glucagon mechanism, which is useful for research distinguishing the glucagon contribution from the GIP contribution within the dual / tri-agonist class. Buyers should not assume mechanistic equivalence between any pair of molecules in this class, the readouts differ enough to matter at the experimental-design level. See our GLP-1 class comparison article for the full side-by-side.
Mazdutide is being developed by Innovent Biologics (China) under license from Eli Lilly, with the partnership reflecting Eli Lilly's strategy of licensing some metabolic-pipeline assets to regional partners for China-focused development while retaining global rights to its own pipeline assets like Retatrutide. The Mazdutide Phase 3 program (DREAMS-1 through DREAMS-3) has reported Phase 3 readouts on weight management and type 2 diabetes endpoints. Chinese regulatory approval is expected to precede Western approval by a meaningful margin, buyers in China can reference local NMPA-pathway documentation for the eventual approval; buyers elsewhere should treat Mazdutide as investigational until further notice.
Both target the same receptor pair (GLP-1R + GCGR, no GIP) and are mechanistically similar at the receptor-coverage level, so the choice between them depends on which sponsor's clinical data your research most needs to align with. Mazdutide (Innovent/Eli Lilly, China-focused development) is the appropriate choice for research benchmarking against Chinese clinical data. Survodutide (Boehringer Ingelheim/Zealand Pharma, global development) is the appropriate choice for benchmarking against EU/US clinical data. The peptide sequences and lipidation chemistries differ, confirm exact identity per batch COA before treating the two as interchangeable in any research context.
Yes. Mazdutide is also stocked as a ready-to-use nasal spray (10 mg) in 10 mL or 20 mL bottles, from 10 bottles of each. These orders ship from our US stock; ask our sales team for details and a quote.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
GLP-1 / glucagon dual receptor agonist (BI 456906)
GIP / GLP-1 / glucagon tri-agonist
Nasal spray availableCapsules available
GIP / GLP-1 dual receptor agonist
Nasal spray available
